<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 17 Apr 2021 11:26:57 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>首款胃癌一线免疫疗法获FDA批准</title><link>https://mp.weixin.qq.com/s/hV1rWTh1N0L_AKgxcLoxwg</link><description></description><content:encoded><![CDATA[首款胃癌一线免疫疗法获FDA批准]]></content:encoded><pubDate>Sat, 17 Apr 2021 10:31:51 +0800</pubDate></item><item><title>Biogen富马酸二甲酯在华获批上市，2020年全球销售额38.41亿美元</title><link>https://mp.weixin.qq.com/s/czylPN1lcXccKVFw2JmCMA</link><description></description><content:encoded><![CDATA[Biogen富马酸二甲酯在华获批上市，2020年全球销售额38.41亿美元]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:55:05 +0800</pubDate></item><item><title>首个STING激动剂获批临床</title><link>https://mp.weixin.qq.com/s/-Y4gZyoCxUuiMoZ71H3mEw</link><description></description><content:encoded><![CDATA[首个STING激动剂获批临床]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:55:05 +0800</pubDate></item><item><title>一年又一年｜CSCO 指南照亮“人间四月天”——乳腺癌领域更新解读（上篇）</title><link>https://mp.weixin.qq.com/s/rHnCwnCzW9oWxcqV4Ih7Ig</link><description></description><content:encoded><![CDATA[一年又一年｜CSCO 指南照亮“人间四月天”——乳腺癌领域更新解读（上篇）]]></content:encoded><pubDate>Fri, 16 Apr 2021 18:55:05 +0800</pubDate></item><item><title>第五批国采60个品种开始报量（附竞争企业清单下载）</title><link>https://mp.weixin.qq.com/s/lU0p6Ix0ZsBn4UnXADKVkA</link><description></description><content:encoded><![CDATA[第五批国采60个品种开始报量（附竞争企业清单下载）]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>辉瑞第三代ALK抑制剂lorlatinib在华申报上市，治疗NSCLC</title><link>https://mp.weixin.qq.com/s/21IkOVxewVCRyTZ9JC40FA</link><description></description><content:encoded><![CDATA[辉瑞第三代ALK抑制剂lorlatinib在华申报上市，治疗NSCLC]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>强生中国区高管「杨炜」出任云顶新耀CSO</title><link>https://mp.weixin.qq.com/s/dPixepU8mM_n6rYMC9dqJA</link><description></description><content:encoded><![CDATA[强生中国区高管「杨炜」出任云顶新耀CSO]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>150亿美元！赛默飞拟收购PPD</title><link>https://mp.weixin.qq.com/s/4ht9yuidEqkWIMjmKm-Oxg</link><description></description><content:encoded><![CDATA[150亿美元！赛默飞拟收购PPD]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>新型口服疗法获FDA突破性疗法认定，治疗1型糖尿病</title><link>https://mp.weixin.qq.com/s/8Mio3dT5jdWR0khSvoHwtg</link><description></description><content:encoded><![CDATA[新型口服疗法获FDA突破性疗法认定，治疗1型糖尿病]]></content:encoded><pubDate>Thu, 15 Apr 2021 15:29:59 +0800</pubDate></item><item><title>PPT+视频回放 | 2021AACR新机会分析</title><link>https://mp.weixin.qq.com/s/sY9eIvTZIiMJpe9Io3hE2A</link><description></description><content:encoded><![CDATA[PPT+视频回放 | 2021AACR新机会分析]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>2021 AACR| 聚焦肿瘤耐药创新疗法！这家公司公布4个项目临床前数据</title><link>https://mp.weixin.qq.com/s/xnmsulkKD9eWi_B-u4yrkg</link><description></description><content:encoded><![CDATA[2021 AACR| 聚焦肿瘤耐药创新疗法！这家公司公布4个项目临床前数据]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>3月肺癌月报 | 振奋！国产三代EGFR-TKI登顶柳叶刀子刊；百济PD-1亮相JAMA Oncol，晚期NSCLC一线战鼓不休</title><link>https://mp.weixin.qq.com/s/E0er9gwlXG4YOMmbRCf_Ng</link><description></description><content:encoded><![CDATA[3月肺癌月报 | 振奋！国产三代EGFR-TKI登顶柳叶刀子刊；百济PD-1亮相JAMA Oncol，晚期NSCLC一线战鼓不休]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>提前6周！吉利德Trop-2 ADC 第2项适应症加速获批，治疗尿路上皮癌</title><link>https://mp.weixin.qq.com/s/vdciN3p_egb_eGxOg9GYKw</link><description></description><content:encoded><![CDATA[提前6周！吉利德Trop-2 ADC 第2项适应症加速获批，治疗尿路上皮癌]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>持续加码神经领域!先声药业first-in-class脑卒中新药获批临床</title><link>https://mp.weixin.qq.com/s/2teZ4v2Ok-ehshZWR4M3Ug</link><description></description><content:encoded><![CDATA[持续加码神经领域!先声药业first-in-class脑卒中新药获批临床]]></content:encoded><pubDate>Wed, 14 Apr 2021 17:31:12 +0800</pubDate></item><item><title>AACR年度学者公布：王晓东、陈列平入选</title><link>https://mp.weixin.qq.com/s/khmu2Gyos97f2zzAe6JErg</link><description></description><content:encoded><![CDATA[AACR年度学者公布：王晓东、陈列平入选]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>华东医药“少女针”获批？</title><link>https://mp.weixin.qq.com/s/yIowbwIg4SOZxkIzFvjxKg</link><description></description><content:encoded><![CDATA[华东医药“少女针”获批？]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>“新华—崇明”医联体集采结果出炉，仅9个品种拟中选</title><link>https://mp.weixin.qq.com/s/rI5WBDpNioltP84O_CfNZQ</link><description></description><content:encoded><![CDATA[“新华—崇明”医联体集采结果出炉，仅9个品种拟中选]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>百济神州公布替雷利珠单抗 vs 化疗治疗NSCLC临床数据</title><link>https://mp.weixin.qq.com/s/WO-wHWYfyWY-ZHmzm-Z1fA</link><description></description><content:encoded><![CDATA[百济神州公布替雷利珠单抗 vs 化疗治疗NSCLC临床数据]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>FibroGen抗CTGF单抗获FDA快速通道资格认定</title><link>https://mp.weixin.qq.com/s/NXpaKzbHe49ctavtM48LIw</link><description></description><content:encoded><![CDATA[FibroGen抗CTGF单抗获FDA快速通道资格认定]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item><item><title>亚盛医药公布5个在研原创新药最新临床进展</title><link>https://mp.weixin.qq.com/s/BxFr-fsU3uVwlT9YCN07Qg</link><description></description><content:encoded><![CDATA[亚盛医药公布5个在研原创新药最新临床进展]]></content:encoded><pubDate>Tue, 13 Apr 2021 18:18:39 +0800</pubDate></item></channel></rss>